If you are comparing Revolax vs Neuramis, do not begin with the brand name. Begin with the result the exact product is expected to support. For fine, subtle correction, the closest starting pair is Revolax Fine versus Neuramis Light Lidocaine. For lower-face folds, compare Revolax Deep with Neuramis Lidocaine and Deep Lidocaine. For cheek or chin structure, the closest broad comparison is Revolax Sub-Q versus Neuramis Volume Lidocaine.
The lip question is less obvious than “Deep versus Deep.” Across, the Korean manufacturer of Revolax, lists Fine, Deep and Sub-Q by placement depth but does not assign a lip-specific role on the cited official product page. The archived Medytox brochure likewise does not name lips in its intended-use table, while Cytollia’s current Neuramis page places lip contour under the plain Neuramis Lidocaine variant. Identical product names therefore do not create a like-for-like match.
There is no defensible overall winner. Neuramis currently has the clearer trail of published product-specific human studies, including 104-week follow-up for Volume Lidocaine in the mid-face. Revolax has a simpler three-step range. Neither fact proves that one brand looks more natural, swells less or lasts longer across every product and treatment area.
The short answer
The answer in 30 seconds
| What you actually want to know | Start by comparing | Direct answer |
|---|---|---|
| Which products fit fine lines or a subtle correction? | Revolax Fine vs Neuramis Light Lidocaine | This is the cleanest role-to-role comparison in the two ranges. |
| Which products fit lower-face folds? | Revolax Deep vs Neuramis Lidocaine and Deep Lidocaine | Neuramis splits this part of the range more finely, so Deep vs Deep alone may miss an option. |
| Which one should be considered for lips? | Confirm the documented use for each exact Revolax and Neuramis variant | Neither cited manufacturer page supports choosing Deep vs Deep from the product name alone. |
| Which products are the structural options? | Revolax Sub-Q vs Neuramis Volume Lidocaine | These are the closest broad roles for cheek/chin volume and facial contouring in the cited materials. |
| Which lasts longer? | No overall winner can be supported | Neuramis Volume has the strongest located long-term data, but only for the studied mid-face setting. |
| Which has stronger product-specific human evidence? | Neuramis | Named Deep and Volume studies are easier to trace; this is an evidence-depth advantage, not proof of superior performance. |
This guide is written for professional product research. Final product selection and treatment remain the responsibility of an appropriately qualified practitioner using the current local instructions for use.
Choose the exact variant
1. Which exact product fits the result you want?
The most useful difference between Revolax and Neuramis is not that one range has three names and the other has four. It is how those names divide the work.
| Desired result or question | Revolax starting point | Neuramis starting point | What matters before deciding |
|---|---|---|---|
| Fine lines and a light, subtle correction | Fine | Light Lidocaine | Both sit at the lighter end of their current ranges. Confirm the exact local intended use. |
| Lower-face wrinkles and nasolabial folds | Deep | Lidocaine or Deep Lidocaine | The Neuramis brochure lists both variants for lower-face folds; the precise distinction must come from the current product information. |
| Lip contour or volume | Confirm the exact intended use; the cited Across page differentiates Fine, Deep and Sub-Q by placement depth, not by a lip label | Cytollia currently positions Neuramis Lidocaine for lip contour; verify the current product information | “Deep vs Deep” is a popular search, not proof of equivalent lip positioning. |
| Cheek or chin augmentation and facial contour | Sub-Q is the deep-subcutaneous option; Deep spans the middle-to-deeper position on Across’s official page | Volume Lidocaine; Cytollia also positions Deep for chin/mid-face | The exact gel role and local instructions matter more than a broad brand comparison. |
| The simplest inventory ladder | Fine → Deep → Sub-Q | Light → Lidocaine → Deep → Volume | Revolax is easier to navigate; Neuramis gives an extra middle step. More options only help when each has distinct demand. |
Check the current Cytollia listings for the complete Revolax Fine / Deep / Sub-Q range and Neuramis Light / Lidocaine / Deep / Volume range before comparing exact variants.
The lip comparison most pages get wrong
Google’s autocomplete surfaces “Revolax Deep vs Neuramis Deep,” and both product names make that comparison look logical. The documentation does not support treating the names as interchangeable.
Across’s official Revolax page separates Fine, Deep and Sub-Q by placement depth: Fine occupies the superficial end, Deep spans the middle-to-deeper position, and Sub-Q occupies the deep-subcutaneous end. It labels all three for temporary improvement of facial wrinkles, but it does not identify a lip-specific Revolax variant on the cited page.
An archived copy of the 2019 Medytox Neuramis brochure lists Light Lidocaine for fine wrinkles, Lidocaine and Deep Lidocaine for lower-face wrinkles and folds, and Volume Lidocaine for cheek/chin augmentation and facial contour. Its intended-use table does not name lips. Cytollia’s current Neuramis listing places lip contour under the plain Lidocaine variant, not Deep.
The practical conclusion is specific: a customer asking about lips should not be given an automatic Revolax Deep vs Neuramis Deep answer. First check the current product information for the exact Revolax and Neuramis variants. Only then is there a real product comparison.
Feel and structure
2. Which feels softer or gives more structure?
The honest brand-level answer is that the current evidence does not prove “Revolax is firmer” or “Neuramis is softer.” Both ranges contain lighter and more structural products, and natural-looking results cannot be reduced to one brand adjective.
Within Revolax, Across’s official specifications show a clear superficial-to-deep progression:
- Fine occupies the superficial end of the manufacturer’s placement table.
- Deep spans the middle-to-deeper position.
- Sub-Q occupies the deep-subcutaneous end.
That progression describes product roles in the official specification; it does not mean that a deeper-positioned product is better for every goal.
Neuramis communicates the same light-to-structural progression through intended use rather than an equally simple thickness statement: Light covers fine wrinkles; Lidocaine and Deep cover lower-face folds; Volume covers cheek/chin augmentation and facial contour.
That gives the customer a more useful way to think about “natural versus firm”:
| Desired finish | Better first comparison | Why this is more useful than choosing a brand |
|---|---|---|
| Light correction with minimal structural emphasis | Revolax Fine vs Neuramis Light Lidocaine | Both are positioned at the lighter end of the range. |
| More definition while retaining movement | Compare the exact mid-range products and the locally documented use | The relevant choice may be Revolax Deep versus Neuramis Lidocaine or Deep, depending on the goal; the names alone do not settle it. |
| Projection and shape retention | Revolax Sub-Q vs Neuramis Volume Lidocaine | Both occupy the structural end of the cited product ranges. |
Why not simply compare 24 mg/mL with 20 mg/mL? Because HA concentration does not independently tell you whether the finished gel is softer, firmer, more cohesive or more prone to swelling. A peer-reviewed 18-product analysis found no clear relationship between isolated HA concentration and swelling factor or cohesion. Gel behavior also depends on crosslinking, elastic modulus, viscosity, cohesivity and the conditions used to measure them.
General rheology helps explain the decision: a gel with greater resistance to deformation can provide more structural support, while a more fluid gel can better conform to movement and superficial tissue. But those principles only become useful when the exact products are measured under comparable conditions. Published research also shows that reported G′ values can change substantially with test settings, so numbers copied from unrelated laboratories should not be turned into a Revolax-versus-Neuramis league table.
The practical question for a consultation is therefore not “Which brand is more natural?” It is: Which exact gel role matches the amount of movement, softness or projection wanted, and what product-specific evidence supports that choice?
Longevity evidence
3. Which lasts longer?
If you want a one-line answer, here it is: the evidence does not show which brand lasts longer overall, but Neuramis has the stronger published product-specific human evidence trail located for this review.
The duration information is not equal on both sides:
| Product evidence | What was actually reported | What it does not prove |
|---|---|---|
| Revolax Fine, Deep and Sub-Q, Across official page | Product lineup and placement-depth specifications; the cited page does not publish product-specific duration data | Does not establish Revolax duration or a comparison with Neuramis. |
| Neuramis Deep vs Restylane, 67 subjects | Randomized matched-pairs study with follow-up through 24 weeks for nasolabial folds | Restylane was the comparator, not Revolax; the result does not transfer to lips or every Neuramis product. |
| Neuramis Deep Lidocaine vs Perlane-L, 58 subjects | Randomized split-face study through 24 weeks for nasolabial folds | Perlane-L was the comparator, not Revolax. |
| Neuramis Volume Lidocaine vs Juvéderm Voluma, 88 subjects | Both sides had a 96.39% response rate at 24 weeks in the studied mid-face endpoint | This is mid-face evidence, not a brand-wide duration promise. |
| Neuramis Volume 104-week extension, 69 extension participants | At week 104, response rates were 73.91% for Neuramis Volume and 72.46% for Juvéderm Voluma | The extension does not compare Neuramis with Revolax and does not predict every individual result. |
The 104-week paper is the most useful longevity evidence found here because it follows an exact product in an exact area for two years. It also has to be read with its limits: 88 Korean subjects entered the original split-face study, 81 completed the 48-week primary study, and 69 entered the extension. One author affiliation and listed funding were from Medytox. Those facts do not invalidate the study, but they belong in an evidence-led interpretation.
The Revolax manufacturer page and the Neuramis studies do not provide the same kind of evidence, so they should not be treated as a head-to-head duration dataset. The responsible conclusion is:
- Choose Neuramis Volume for further review when published long-term mid-face evidence is a priority.
- Do not claim that Neuramis as a whole lasts longer than Revolax.
- Do not use a mid-face Volume study to promise lip duration.
- Expect individual longevity to vary with the exact product, treated area, movement, biology and treatment plan.
Swelling and safety
4. Which causes less swelling?
No direct evidence located for this review shows that Revolax causes less swelling than Neuramis or vice versa. Reviews and forum comments may reveal what customers worry about, but conflicting anecdotes cannot establish a product-level safety ranking.
The FDA’s dermal filler guidance lists swelling, bruising, redness, pain and tenderness among common risks. Many early effects resolve in days to weeks, although timing varies. The same guidance warns that unintended injection into a blood vessel can cause tissue death, visual impairment, blindness or stroke. Unusual pain, vision changes, pale or discoloured skin near the treatment area, or stroke-like symptoms require immediate medical attention.
Three practical points answer the comparison more honestly:
- Do not judge a brand from an immediate after-photo. Early swelling can change apparent volume and symmetry, so result timing should follow the treating professional’s product-specific guidance.
- Do not use 24 mg/mL versus 20 mg/mL as a swelling prediction. The cited rheology study found no clear relationship between isolated HA concentration and swelling factor.
- Lidocaine is not a swelling score. All seven variants currently listed by Cytollia contain 0.3% lidocaine. That formulation detail may support injection comfort, but it does not prove that either brand has less post-treatment swelling.
The decision should be based on qualified assessment, the exact product and current local product information—not on a promise that one Korean filler brand is “swelling-free.”
Evidence depth
5. Which brand has stronger clinical evidence?
The direct answer is Neuramis—for named products and named treatment areas. That does not mean every Neuramis filler is clinically better than every Revolax filler. It means the evidence located for this review is easier to trace from an exact product to a human study.
| Customer question | Neuramis evidence located | Revolax evidence located | Defensible conclusion |
|---|---|---|---|
| Lower-face folds | Neuramis Deep was studied against Restylane in 67 subjects; Deep Lidocaine was studied against Perlane-L in 58 subjects, both through 24 weeks | No comparable Revolax product-specific human study was identified in the search | Neuramis has the clearer evidence path for named lower-face products; this does not prove superiority over Revolax. |
| Mid-face volume | Neuramis Volume was studied against Juvéderm Voluma in 88 subjects, with a 69-subject extension through 104 weeks | No comparable Revolax product-specific human study was identified in the search | Neuramis Volume has the strongest located long-term human evidence in this comparison. |
| Lips | The cited Neuramis product materials and studies do not establish a Revolax-versus-Neuramis lip winner | Across’s official specifications do not provide a Revolax-versus-Neuramis lip study or identify an evidence-based lip winner | Neither brand can be called the evidence-based lip winner. |
| Whole-brand comparison | No direct Revolax comparison was identified | No direct Neuramis comparison was identified | A brand-wide efficacy, naturalness, longevity or safety ranking is unsupported. |
This distinction matters because more published evidence is not the same as better performance. A product can have fewer accessible studies for many reasons; absence of a located trial does not prove that it performs poorly. It does mean an article should not fill the evidence gap with reviews, slogans or unrelated laboratory numbers.
If evidence confidence is the deciding factor, start with the exact Neuramis study that matches the question: Deep or Deep Lidocaine for lower-face folds, and Volume Lidocaine for mid-face volume. If the question is lips or a direct brand winner, the current evidence does not provide a clean answer.
The practical decision
Bottom line: which one should you inspect first?
- Inspect Revolax first when you want a simple Fine–Deep–Sub-Q ladder documented by the Korean manufacturer from superficial to deep-subcutaneous positioning. This is range clarity, not proof of a better result.
- Inspect Neuramis first when traceable human evidence matters most. Volume Lidocaine has the strongest long-term evidence located, but only for the studied mid-face setting.
- Do not choose either brand from the words “Deep,” “natural” or “24 mg/mL.” There is no direct evidence that either entire brand looks more natural, causes less swelling or lasts longer than the other.
For lips, confirm the documented use for the exact Revolax and Neuramis variants before comparing them. For structural cheek/chin research, begin with Sub-Q versus Volume. For fine lines, begin with Fine versus Light. That product-level match is the decision; the brand name is only the container.
Product routes
Compare the current options
REVOLAX® HA DERMAL FILLER
Fine / Deep / Sub-Q
View the current Cytollia product page →
NEURAMIS® HA DERMAL FILLER
Light / Lidocaine / Deep / Volume
View the current Cytollia product page →
Use the exact variant name and current product information when comparing options. You can also browse all Cytollia dermal filler products or continue reading the Dermal Filler Guides. If you need a product-specific document, contact Cytollia before ordering.
Evidence notes
Primary sources and evidence notes
- Across official Revolax page: Korean manufacturer specifications for Revolax Fine, Deep and Sub-Q, including the official superficial-to-deep placement progression; not independent comparative evidence.
- Medytox official Neuramis page and an archived copy of its 2019 product brochure: family structure, 1.0 mL format and historical intended-use fields; manufacturer/data-on-file claims are not independent superiority evidence.
- Pak et al., Neuramis Deep vs Restylane: randomized 67-subject matched-pairs nasolabial-fold study through 24 weeks.
- Joo et al., Neuramis Deep Lidocaine vs Perlane-L: randomized 58-subject split-face nasolabial-fold study through 24 weeks.
- Jung et al., Neuramis Volume vs Juvéderm Voluma: 88-subject split-face mid-face study with identical 96.39% response rates at 24 weeks.
- Jung et al., 104-week extension: long-term Neuramis Volume mid-face follow-up; Medytox affiliation and funding are disclosed in PubMed.
- Fagien et al., HA filler rheology: supports the boundary that isolated HA concentration does not determine swelling or cohesion.
- FDA dermal filler risks: general common effects and serious warning signs; not a product-specific comparison.
- Current Cytollia product pages: Revolax and Neuramis, checked 30 August 2026 for listed variants and availability.
Commercial and review disclosure: Cytollia sells both product families. The article separates manufacturer marketing from human evidence, does not claim manufacturer endorsement and does not recommend an injectable product for an individual. Licensed medical review is recommended before using this information in clinical decisions.